Absci uses artificial intelligence to design antibody drugs and is testing its lead candidate in clinical trials. It last closed at $7.58 on Nov 17, up 1.40% on the day. ABSI last reported earnings on Tue, Aug 11, 2026. The average 12-month price target from 7 analysts is $15.71 (+107.3% from the last close), with a high of $20.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).
Each firm's latest rating on ABSI in the past 90 days
Average 12-month target
$15.71
▲ 107.3% upside
Based on 7 analysts who set a price target on ABSI in the past 90 days. The average target is $15.71, with a high of $20.00 and a low of $14.00, compared with the last close of $7.58.
Highest target$20.00
Average target$15.71
Lowest target$14.00
Latest rating changes
GuggenheimTarget lowered
Nov 16Buy$15 → $14
NeedhamTarget raised
Nov 13Buy$11 → $15
JefferiesInitiated
Oct 29Buy$14
KeybancMaintained
Oct 16Buy$20
JP MorganMaintained
Oct 12Buy$15
Date
Firm
Action
Rating
Price target
Nov 16
Guggenheim
Target lowered
Buy
$15 → $14
Nov 13
Needham
Target raised
Buy
$11 → $15
Oct 29
Jefferies
Initiated
Buy
$14
Oct 16
Keybanc
Maintained
Buy
$20
Oct 12
JP Morgan
Maintained
Buy
$15
Loading…
Technical Analysis
ABSI · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold
The stock is 30% below its 20 day and 27% below its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $7.56, and the nearest resistance the Pivot R1 at $7.77.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 13.2%/day
Key levels
$12.5452 week high+65.4%
$9.8520 day average+29.9%
$9.6050 day average+26.6%
$9.40100 day average+24.0%
$8.17Swing high (Jun 15)+7.8%
$7.77Pivot R1+2.5%
$7.58Last close
$7.56Pivot−0.3%
$7.36Pivot S1−2.9%
$6.88200 day average−9.2%
$6.69Swing low (Jul 29)−11.7%
$2.2452 week low−70.4%
Indicators
RSI (14)
38.48
Weak, oversold below 30
Neutral
MACD
-0.37
Below its signal line
Bearish
Stochastic
4.0
Near the bottom of its range
Oversold
ADX (14)
15.4
No clear trend
Williams %R
-94.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-187.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−24.2%
Change over 10 sessions
Bearish
ATR (14)
$1.00
Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 24.0%/day
Key levels
$12.5452 week high+65.4%
$9.8520 day average+29.9%
$9.6050 day average+26.6%
$9.40100 day average+24.0%
$8.17Swing high (Jun 15)+7.8%
$7.77Pivot R1+2.5%
$7.58Last close
$7.56Pivot−0.3%
$7.36Pivot S1−2.9%
$6.88200 day average−9.2%
$6.69Swing low (Jul 29)−11.7%
$2.2452 week low−70.4%
Indicators
RSI (14)
46.98
Middle of its range
Neutral
MACD
0.70
Below its signal line
Bearish
Stochastic
24.4
Middle of its range
Neutral
ADX (14)
39.2
Trending up
Williams %R
-94.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-131.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−7.7%
Change over 10 sessions
Bearish
ATR (14)
$1.82
Typical daily range, 24.0% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for ABSI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ABSI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ABSI usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ABSI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABSI is in one of them and how their past ABSI trades turned out.
Absci is a biopharmaceutical company based in Vancouver, Washington. It uses artificial intelligence to design antibody therapeutics aimed at biological targets that have received little prior research. Its lead candidate, ABS-201, is in clinical trials for hair loss and is planned for testing in endometriosis. The company also creates drug candidates with pharmaceutical partners for their own pipelines.